Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03862430 · ClinicalTrials.gov registry record · Phase 2
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
A Phase 2 study of Glioblastoma Multiforme, sponsored by NuvOx.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 12
- Study locations
NCT03862430 is a Phase 2 study of Glioblastoma Multiforme that is active but no longer recruiting, run by NuvOx. The registered enrollment target is 87 participants, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The trial reports 12 study locations across 10 states.
The verdict
NCT03862430, a Phase 2 study of Glioblastoma Multiforme, is active but no longer recruiting, sponsored by NuvOx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 12
- Study locations
Study Summary
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Conditions Studied
Interventions
- DRUG NanO2TM
- DRUG Placebo Saline Infusion
Study Locations (12)
Arizona
- Center for Neurosciences - Tucson
- University of Arizona - Tucson
California
- UC Irvine Health- Chao Family Comprehensive Cancer Center - Orange
- Providence St. John's Cancer Institute - Santa Monica
Connecticut
- Yale Cancer Center - New Haven
Illinois
- St. Francis Medical Center, OSF Healthcare - Peoria
Louisiana
- Ochsner Clinic Foundation - New Orleans
Missouri
- Saint Luke's Cancer Institute - Kansas City
New Jersey
- Atlantic Health System - Summit
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03862430
The ClinicalTrials.gov registry entry for NCT03862430 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The listed sponsor is NuvOx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which NanO2TM is the first listed.
NCT03862430 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03862430 about?
NCT03862430 is a clinical study titled "A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM". This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation ...
What is the current status of trial NCT03862430?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2023-03-31. Estimated completion is 2026-09-30.
What conditions does trial NCT03862430 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT03862430?
The interventions under investigation include: NanO2TM (DRUG), Placebo Saline Infusion (DRUG).
Who is sponsoring clinical trial NCT03862430?
This trial is sponsored by NuvOx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03862430 being conducted?
This trial has 12 study locations across Arizona, California, Connecticut, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.